Küresel bir tehdit: Acinetobacter baumannii enfeksiyonları, antimikrobiyal dirençte güncel durum ve alternatif tedavi yaklaşımları

Öz

Acinetobacter baumannii ventilatör ilişkili pnömoni ve kateter ilişkili bakteriyemi başta olmak üzere, idrar yolu enfeksiyonları, yumuşak doku enfeksiyonları, septisemi ve menenjit gibi ciddi enfeksiyonlara neden olan önemli nozokomiyal patojenlerden birisidir. Polisakkarit kapsül, fimbria, Lipit A ve lipopolisakkarit yapı gibi çeşitli virülans faktörlerinin yanı sıra siderofor, sekresyon sistemleri, biyofilm oluşturma özelliği ve antibiyotik direnç genleri bakterinin patogenezine katkı sağlamaktadır. Karbapenemler, aminoglikozitler, sulbaktam, kolistin ve tigesiklin ciddi klinik tablolara neden olan Acinetobacter enfeksiyonlarının tedavisinde sıklıkla kullanılan antimikrobiyal ajanlardır. Karbapenemlere direnç, genellikle çoklu ilaç direnci ÇİD ile birlikte görülmektedir. Dirençli izolatların tedavisinde kullanılan tigesiklin ve kolistine dahi çeşitli merkezlerde artan direnç oranları rapor edilmekte, bu durum A. baumannii enfeksiyonlarının tedavisini ve eradikasyonunu oldukça zorlaştırmaktadır. A. baumannii’de antimikrobiyal direnç durumunun ulaştığı endişe verici boyut, 2018 yılında Dünya Sağlık Örgütü tarafından yayınlanan ‘yeni antibiyotik keşfi gerektiren dirençli bakteriler’ listesinin ilk sırasında bu bakteri türünün yer almasıyla açıkça ortaya konmuştur. Antimikrobiyal dirençle mücadele ve etkin tedavi açısından bakterinin virülans faktörlerinin ve direnç mekanizmalarının daha iyi anlaşılması oldukça önemlidir. Çoklu ilaç dirençli bakterilerle mücadele global bir sağlık problemi haline gelmiş olup A. baumannii’nin de içinde bulunduğu bu tür dirençli mikroorganizmalar ile mücadelede enfeksiyon kontrol önlemleri, akılcı antibiyotik kullanımı ve antivirülans stratejilerinin bütüncül bir yaklaşımla bir arada kullanılması gerekmektedir. Bu bağlamda, kombine antibiyotik kullanımı, eflüks pompa inhibitörleri, antibiyofilm ajanların kullanımı ve faj terapisi gibi alternatif tedavi potansiyeli olduğu düşünülen alanlarda yürütülen araştırmalar büyük önem taşımaktadır. Bu derlemede; A. baumannii’nin patogenezinde rol oynayan faktörler, epidemiyolojik özellikleri ve antibiyotik direnç mekanizmaları hakkında güncel bilgilere yer verilmiş ve bu patojenle mücadelede öne çıkan alternatif tedavi yaklaşımları incelenmiştir

Anahtar Kelimeler

• Acinetobacter baumannii, antibiyotik direnci, virülans faktörleri

A global threat: Acinetobacter baumannii infections, current condition in antimicrobial resistance and alternative treatment approaches

Abstract

Acinetobacter baumannii is an important nosocomial pathogens that cause serious infections such as ventilator-associated pneumonia, catheterrelated bacteriemia, urinary tract infections, soft tissue infections, septicemia and meningitis. Various virulence factors such as polysaccharide capsule, fimbria, lipid A and lipopolysaccharide structure, siderophore, secretion systems, biofilm formation and antibiotic resistance genes contribute to the pathogenesis of the bacteria. Carbapenems, aminoglycosides, sulbactam, colistin and tigecycline are frequently used antimicrobial agents in Acinetobacter infections. Resistance to carbapenems is usually seen as multidrug resistance MDR . As reported from various centers, the development of resistance to tigecycline and colistin, used in the treatment of MDR isolates, makes treatment of A. baumannii infections more difficult. In 2018, the World Health Organization published ‘global priority list of antibiotic-resistant bacteria requiring new antibiotic discovery’ and A. baumannii has been at the top of this list. The alarming dimension of the antimicrobial resistance in A. baumannii was clearly demonstrated by this report. Understanding of the virulence and resistance mechanisms of the bacterium is essential for effective treatment and fighting antibiotic resistance. In combating MDR bacteria that have become a global health problem such as A. baumannii, infection control preventions, rational antibiotic use and anti-virulence strategies need to be used in a holistic approach. The studies carried on alternative therapies such as combined antibiotic use, efflux pump inhibitors, anti-biofilm agents and phage therapy are of great importance. In this review; the current knowledge about the factors involved in pathogenesis of A. baumannii, its epidemiological characteristics, antibiotic resistance mechanisms and alternative treatment approaches for combating had been evaluated.

Keywords

• Acinetobacter baumannii, antibiotic resistance, virulence factors

Kaynakça

1. 1. Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence, 2012;3(3):243-50. doi:10.4161/viru.19700.
2. 2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev, 2008;21(3):538- 82. doi:10.1128/CMR.00058-07.
3. 3. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol, 1991;29(2):277-82. doi:10.1128/jcm.44.3.827- 832.2006.
4. 4. Doi Y, Murray GL, Peleg AY, Hospital A. HHS Public Access. Semin Respir Crit Care Med, 2016;36(1):85-98. doi:10.1055/s-0034-1398388.
5. 5. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev, 2017;30(1):409- 47. doi:http://dx.doi.org/10.1128/ CMR.00058-16.
6. 6. Erac B, Yilmaz FF, Hosgor LM, Ozturk I, Aydemir S. Investigation of the virulence factors of multidrug-resistant Acinetobacter baumannii isolates. Mikrobiyol Bul, 2014;48(1):70-8.
7. 7. Erdem B. Mikrobiyal sideroforlar ve biyoteknolojideki uygulama alanları. Karadeniz Fen Bilim Derg. 2013;3(8):77-88.
8. 8. Kraemer SM. Iron oxide dissolution and solubility in the presence of siderophores. Aquat Sci, 2004;66(1):3-18. doi:10.1007/s00027-003-0690- 5.

9. 9. Lee C-R, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front Cell Infect Microbiol, 2017;7(March). doi:10.1007/ BF00449040.
10. 10. Asık G. Acinetobacter baumannii Virülansının Açıklanmasında Güncel Yaklaşımlar Acinetobacter baumannii. Mikrobiyol Bul, 2011;45(2):371-80.
11. 11. Fleming D, Rumbaugh KP. Approaches to Dispersing Medical Biofilms. Microorganisms. 2017;5(2):15. doi:10.3390/microorganisms5020015
12. 12. Temel A, Erac B. Bacterial Biofilms:Detection Methods And Role In Antibiotic Resistance. Türk Mikrobiyol Cem Derg, 2018;48(1):1-13 doi:10.5222/TMCD.2018.001.
13. 13. Eze EC, Chenia HY, Zowalaty ME El. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist, 2018;(11):2277-99. doi:10.2147/IDR. S169894.
14. 14. Loehfelm TW, Luke NR, Campagnari AA. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J Bacteriol, 2008;190(3):1036-44. doi:10.1128/JB.01416-07.
15. 15. Bardbari AM, Arabestani MR, Karami M, Keramat F, Alikhani MY, Bagheri KP. Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental Acinetobacter baumannii isolates. Microb Pathog, 2017;108:122-8. doi:10.1016/j.micpath.2017.04.039.
16. 16. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gramnegative bacterial pathogens. Int J Med Microbiol, 2010;300(6):371-9. doi:10.1016/j. ijmm.2010.04.005.
17. 17. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol, 1998;36(7):1938-41.
18. 18. J. Towner K. The Genus Acinetobacter. In: Prokaryotes. Vol 4. ; 2006:746-58. doi:10.1007/0-387-30746-X_25.
19. 19. Kireçci E, Kireçci M, Aksu M. Investigation of the Antibiotic Susceptibility of Acinetobacter baumannii Strains Isolated from Clinical Samples. Türk Mikrobiyol Cem Derg, 2014;44(2):65-69. doi:10.5222/TMCD.2014.065.
20. 20. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents, 2010;35(3):219-26. doi:10.1016/j. ijantimicag.2009.10.024.
21. 21. Ece G, Erac B, Cetin HY, Ece C, Baysak A. antimicrobial susceptibility and clonal relation between Acinetobacter baumannii strains at a tertiary care center in Turkey. Jundishapur J Microbiol, 2015; 8(2): e15612.
22. 22. Clark NM, Zhanel GG, Lynch JP. Emergence of antimicrobial resistance among Acinetobacter species: A global threat. Curr Opin Crit Care, 2016;22(5):491-9. doi:10.1097/ MCC.0000000000000337.
23. 23. Gozutok F, Mutlu Sariguzel F, Celik I, Berk E, Aydin B, Guzel D. Investigation of Antimicrobial Resistance Rates of Acinetobacter baumannii Strains from Nosocomial Infections. Ankem Derg, 2013;27(1):7-12. doi:10.5222/ankem.2013.007.
24. 24. Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi J Biol Sci, 2018;25(3):586-96. doi:10.1016/j.sjbs.2016.02.009.
25. 25. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents, 2008;32(2):106-19. doi:10.1016/j. ijantimicag.2008.02.013.
26. 26. Karah N, Sundsfjord A, Towner K, Samuelsen Ø. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat, 2012;15(4):237-47. doi:10.1016/j. drup.2012.06.001.
27. 27. Ocak M, Ozer B, Inci M, Duran N. Antibiotic Resistance and Investigation of IMP-1, IMP2, VIM-1 and VIM-2 Metallo-β-Lactamases in Acinetobacter Strains Isolated From Clinical Samples. Klimik Dergisi, 2015;28(1):23-7. doi:10.5152/kd.2015.05.
28. 28. Chen H, Cao J, Zhou C, Liu H, Zhang X, Zhou T. Biofilm Formation Restrained by Subinhibitory Concentrations of Tigecyclin in Acinetobacter baumannii Is Associated with Downregulation of Efflux Pumps. Chemotherapy, 2017;62(2):128- 33. doi:10.1159/000450537.
29. 29. Decousser JW, Jansen C, Nordmann P , Emirian A , Bonnin RA , Anais L, et al. Outbreak of NDM-1-producing Acinetobacter baumannii in France, January to May 2013. Euro Surveill Bull Eur sur les Mal Transm = Eur Commun Dis Bull, 2013;18(31).
30. 30. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother, 2003;51(3):565-74.
31. 31. Krizova L, Poirel L, Nordmann P, Nemec A. TEM1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. J Antimicrob Chemother, 2013;68(12):2786-91. doi:10.1093/jac/dkt275.
32. 32. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB twocomponent regulatory system. Antimicrob Agents Chemother, 2011;55(7):3370-9. doi:10.1128/AAC.00079-11.
33. 33. Arroyo LA, Herrera CM, Fernandez L, Hankins J V, Trent MS, Hancock REW. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother, 2011;55(8):3743-51. doi:10.1128/AAC.00256- 11.
34. 34. Geisinger E, Isberg RR. Interplay between antibiotic resistance and virulence during Disease promoted by multidrug-resistant bacteria. J Infect Dis, 2017;215(Suppl 1):S9- S17. doi:10.1093/infdis/jiw402.
35. 35. Ciftci IH, Asik G. Antibiotic Resistance Mechanisms of Acinetobacter baumannii. ANKEM Derg, 2011;25(3):196-207. doi:10.5222/ ankem.2011.196.
36. 36. Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother, 2007;59(6):1210-5. doi:10.1093/ jac/dkl509
37. 37. Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother, 2011;55(3):947- 3. doi:10.1128/AAC.01388-10.
38. 38. Wieczorek P, Sacha P, Hauschild T, Zórawski M, Krawczyk M, Tryniszewska E. Multidrug resistant Acinetobacter baumannii - The role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol, 2008;46(3):257-7. doi:10.2478/v10042-008- 0056-x.
39. 39. He X, Lu F, Yuan F, Jiang D , Zhao P , Zhu J et al. Biofilm formation caused by clinical acinetobacter baumannii isolates is associated with overexpression of the AdeFGH efflux pump. Antimicrob Agents Chemother, 2015;59(8):4817- 25. doi:10.1128/AAC.00877-15.
40. 40. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, et al. Comparison of colistincarbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis, 2014;33(8):1311-22. doi:10.1007/s10096-014-2070-6.
41. 41. Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: A systematic review and network meta-analysis. J Antimicrob Chemother, 2018;73(1):22-32. doi:10.1093/jac/ dkx368.
42. 42. Zhang Y, Brackman G, Coenye T. Pitfalls associated with evaluating enzymatic quorum quenching activity: the case of MomL and its effect on Pseudomonas aeruginosa and Acinetobacter baumannii biofilms. PeerJ, 2017;5:e3251. doi:10.7717/peerj.3251.
43. 43. Seo H, Kim J, Jung J, Jin HM, Jeon CO, Park W. Complexity of cell-cell interactions between Pseudomonas sp. AS1 and Acinetobacter oleivorans DR1: Metabolic commensalism, biofilm formation and quorum quenching. Res Microbiol, 2012;163(3):173-81. doi:10.1016/j. resmic.2011.12.003.
44. 44. Bai X, Wu F, Zhou B, Zhi X. Biofilm bacterial communities and abundance in a full-scale drinking water distribution system in Shanghai. J Water Health, 2010;8(3):593-600. doi:10.2166/ wh.2010.048.
45. 45. Hauser AR, Mecsas J, Moir DT. Beyond antibiotics: New therapeutic approaches for bacterial infections. Clin Infect Dis, 2016;63(1):89-95. doi:10.1093/cid/ciw200.
46. 46. Kusradze I, Karumidze N, Rigvava S, Dvalidze T, Katsitadze M, Amiranashvili I, et al. Characterization and Testing the Efficiency of Acinetobacter baumannii Phage vB-GEC_AbM-G7 as an Antibacterial Agent. Front Microbiol, 2016;7:1590. https://www.frontiersin.org/ article/10.3389/fmicb.2016.01590.
47. 47. Jeon JH, Lee JH, Lee JJ, Park KS, Karim MA, Lee CR et al. Structural Basis for CarbapenemHydrolyzing Mechanisms of Carbapenemases Conferring Antibiotic Resistance. Int J Mol Sci, 2015;16(5):9654-92. doi:10.3390/ ijms16059654.
48. 48. Rodríguez-Rubio L, Chang WL, Gutiérrez D, Lavigne R , Martínez B, Rodríguez A et al. ‘Artilysation’ of endolysin λSa2lys strongly improves its enzymatic and antibacterial activity against streptococci. Sci Rep, 2016;6(June):1- 11. doi:10.1038/srep35382.
49. 49. Park YK, Ko KS. Effect of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) on killing Acinetobacter baumannii by colistin. J Microbiol, 2015;53(1):53-9. doi:10.1007/ s12275-015-4498-5.
50. 50. 5World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available at: http://www.who. int/medicines/publications/WHO-PPL-Short_ Summary_25Feb ET_NM_WHO.pdf. Accessed October 10, 2018.